Radiation Oncology/RTOG Trials/9601
RTOG 96-01 (PROSTATE)
- Title: A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy For pT3N0 Carcinoma of the Prostate
- (1) To compare overall survival outcome of radiation therapy plus Casodex to radiation therapy plus placebo by a randomized trial for patients who, following radical prostatectomy demonstrating pathologic T3 disease and pathologic N0 disease status, have an elevated PSA (either as persistence or as a relapse) and have no evidence of metastatic disease.
- (2) To compare the treatment with respect to time to second PSA-based progression, time to distant failure, and disease-specific survival.
- (3) To compare the treatment with respect to time to third PSA failure (or PSA progression on hormonal therapy for second PSA failure) as a potential predictor for impending cancer death.
- Arm 1: 64.8 Gy RT + Casodex x2 years
- Arm 2: 64.8 Gy RT
- Status post RP
- pT3 or (pT2 with +SM) AND post-op PSA 0.2-4
- Enrollment Target: 810 patients
- Activation: March 17, 1998
- Closed: March 7, 2003